Why XBiotech Inc.’s (XBIT) Stock Is Up 6.89%
As of Thursday, March 19, XBiotech Inc.’s XBIT share price has surged by 6.89%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Commentary & Analysis
Why XBiotech Inc.’s (XBIT) Stock Is Up 5.12%
As of Friday, March 13, XBiotech Inc.’s XBIT share price has surged by 5.12%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why XBiotech Inc.’s (XBIT) Stock Is Down 5.53%
As of Thursday, March 05, XBiotech Inc.’s XBIT share price has dipped by 5.53%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why XBiotech Inc.’s (XBIT) Stock Is Up 5.19%
As of Tuesday, February 10, XBiotech Inc.’s XBIT share price has surged by 5.19%, which has investors questioning if this is right time to sell.Jenna Brashear
Why XBiotech Inc.’s (XBIT) Stock Is Down 5.68%
As of Thursday, January 15, XBiotech Inc.’s XBIT share price has dipped by 5.68%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | XBIT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $68.0 | $252.6 | 18% |
|
| Shares Out (Mil) | 30.5 | 52.3 | 37% |
|
| Institutional Ownership | 21.3% | 92.1% | 10% |
|
| Float (Mil) | 22.8 | 40.2 | 31% |
|
| Beta | 0.86 | 0.95 | 51% |
|
| Avg Daily Volume (000s) | 43 | 455 | 27% |
|
| Price Change (52-week) |
(23.1%) | 52.9% | 29% |
|
| Growth | XBIT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (32.4%) | (9.9%) | 12% |
|
| EPS (5yr) | (32.6%) | 16.0% | 7 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 36.9% | (15.6%) | 89% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | XBIT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($40) | ($43) | 18% |
|
| EPS (TTM) | ($1.317) | ($1.600) | 19% |
|
| Operating Cash Flow (TTM) (Mil) | ($42) | ($31) | 10% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $5 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($41) | $180 | 1% |
|
| Valuation | XBIT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.50 | 2.56 | 9% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | XBIT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (25.0%) | (49.8%) | 19% |
|
| ROE | (25.9%) | (55.5%) | 21% |
|
| Liabilities to Assets | 3.4% | 30.3% | 1% |
|
| F-Score | 2 | 3 | 7% |
|
Passing Stock Screens
As of 7/31/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Schloss Screen
Factors: Value, Quality
This screen looks for stocks hitting new lows, trading at a price lower than book value per share, with no debt and high levels of insider ownership.
| Performance Since Inception: | 0.7% |
| +/- S&P 500: | -6.8 |
